SMO and cancer: Aberrant Hh activation in cancer can also arise through non-canonical/SMO independent signaling linked to a number of different oncogenic pathways, such as PI3K/AKT, RAS-RAF-MEK-ERK signaling, KRAS constitutive activation, and TGF-beta.